Repository logo
 
Publication

Serum neutrophil biomarkers to predict crohn's disease progression and infliximab treatment outcomes

2024-12-08Journal article Open access
Simple item page
dc.contributor.authorMagalhaes, D.
dc.contributor.authorSantiago, M.
dc.contributor.authorPatita, M.
dc.contributor.authorArroja, B.
dc.contributor.authorLago, P.
dc.contributor.authorRosa, I.
dc.contributor.authorSousa, Helena Tavares
dc.contributor.authorMinistro, P.
dc.contributor.authorMocanu, I.
dc.contributor.authorVieira, A.
dc.contributor.authorCastela, J.
dc.contributor.authorMoleiro, J.
dc.contributor.authorRoseira, J.
dc.contributor.authorEugenia, C.
dc.contributor.authorSousa, P.
dc.contributor.authorPortela, F.
dc.contributor.authorCorreia, L.
dc.contributor.authorDias, S.
dc.contributor.authorAfonso, J.
dc.contributor.authorDanese, S.
dc.contributor.authorPeyrin‐Biroulet, L.
dc.contributor.authorDias, C. C.
dc.contributor.authorMagro, F.
dc.date.accessioned2025-01-10T10:55:20Z
dc.date.available2025-01-10T10:55:20Z
dc.date.issued2024-12-08
dc.description.abstractBackground and aims: Predicting the treatment outcomes of biological therapies is an unmet need in Crohn's Disease. In this study, we explored the potential of serum neutrophil-related biomarkers to predict infliximab therapeutic results and disease progression in Crohn's Disease patients, over a 2-year period, in a real-world setting. Methods: The study included 100 asymptomatic Crohn's Disease patients in the IFX maintenance phase from the prospective, observational, multicenter DIRECT study. Patients were categorized according to a composite outcome reflecting progression that included surgery, hospitalizations, new fistulae, abscess or stricture, and drug treatment escalation. Serum neutrophil elastase, lipocalin-2, lactoferrin, and resistin (non-neutrophil control) were analyzed via multiplex magnetic bead assays at multiple touchpoints. Fecal calprotectin was assessed by ELISA. Results: Over up to 2 years of follow-up, serum biomarkers did not differentiate between the composite outcome groups, whereas fecal calprotectin was significantly higher in patients with worse outcomes. During the infliximab maintenance phase, there was a significant, sustained reduction of neutrophil elastase (p < 0.001), lipocalin-2 (p < 0.001), and lactoferrin (p < 0.001), but not of resistin, despite stable neutrophil levels. Correlations between NE and NGAL levels were strong (Pearson correlations 0.75-0.85); all other correlations were of small magnitude. Conclusion: Our real-world data do not support using serum neutrophil elastase, lipocalin-2, or lactoferrin concentrations as predictors of treatment outcomes or disease evolution in infliximab -treated Crohn's Disease patients. On the other hand, the sustained decrease in biomarkers over time suggests that neutrophil stabilization might be an additional infliximab mechanism of action.eng
dc.identifier.doi10.1002/ueg2.12712
dc.identifier.issn2050-6406
dc.identifier.issn2050-6414
dc.identifier.urihttp://hdl.handle.net/10400.1/26604
dc.language.isoeng
dc.peerreviewedyes
dc.publisherWiley
dc.relation.ispartofUnited European Gastroenterology Journal
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCrohn's disease
dc.subjectFecal calprotectin
dc.subjectInfliximab
dc.subjectLactoferrin
dc.subjectL'ipocalin-2
dc.subjectNeutrophil elastase
dc.subjectResistin
dc.subjectSerum neutrophil biomarkers
dc.titleSerum neutrophil biomarkers to predict crohn's disease progression and infliximab treatment outcomeseng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage1
oaire.citation.titleUnited European Gastroenterology Journal
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameSousa
person.givenNameHelena Tavares
person.identifier.ciencia-idCF1F-1163-1C4A
person.identifier.orcid0000-0002-6626-205X
relation.isAuthorOfPublication6b1d11dd-486f-4fb3-b41f-02e1cf6a5c2e
relation.isAuthorOfPublication.latestForDiscovery6b1d11dd-486f-4fb3-b41f-02e1cf6a5c2e

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
UEG Journal - 2024 - Magalhaes - Serum Neutrophil Biomarkers to Predict Crohn s Disease Progression and Infliximab.pdf
Size:
705.39 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ABC2-Artigos (em revistas ou actas indexadas)
ULS_10.1-MED-Artigos